Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
ACE-031
A myostatin-pathway modulator studied in muscle-mass and strength research.
- Half-life (approx.)
- ~2–3 weeks (approx., fusion protein)
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 1 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
ACE-031 is a soluble ActRIIB fusion protein that antagonizes myostatin-family ligands in muscle-research models. Preclinical work examines lean-mass changes and strength endpoints under controlled laboratory conditions. Investigational ActRIIB decoy — clinical development halted after safety review.
Structure & identity
Recombinant ActRIIB/IgG1-Fc fusion protein
- Sequence / structure
- Recombinant ActRIIB/IgG1-Fc fusion protein
Status: Investigational; development halted in clinical trials.
Mechanism
Investigational; development halted in clinical trials.
Soluble ActRIIB decoy receptor traps activins and myostatin, disinhibiting muscle growth signaling. TGF-β superfamily ligand sequestration disinhibits muscle anabolism signaling in preclinical models.
Studies & clinical programs
Duchenne muscular dystrophy models
Published research models
- Peer-reviewed literature documents endpoints under Duchenne muscular dystrophy models experimental designs.
Lean mass rodent studies
Published research models
- Peer-reviewed literature documents endpoints under Lean mass rodent studies experimental designs.
Research models in literature
- Duchenne muscular dystrophy models
- Lean mass rodent studies
Literature highlights
- ActRIIB decoy receptor mechanism evaluated in Duchenne muscular dystrophy and lean-mass trials.
- Myostatin and activin ligand trapping studied via muscle biopsy and imaging endpoints.
- Clinical development halted after safety signals — literature remains preclinical reference for TGF-β superfamily modulation.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Refrigerated (2–8 °C); do not shake vial | Recombinant proteins and glycoproteins require gentle handling; inspect cake integrity and store upright per IU potency literature. |
| Reconstituted | Manufacturer diluent or bacteriostatic water, refrigerated | Swirl gently until dissolved — never shake vigorously; refrigerated stability is often shorter than small peptides (days to ~2 weeks). |
| Working aliquots | Frozen (−20 °C) in protein-grade tubes | Aliquot by IU or mg immediately after reconstitution; label concentration and avoid foam formation during draw. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 1 | 1 | 1000.0 | 10 | 25 | 50 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Typically reconstituted per research protocol; concentration varies by published formulation.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance